• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down 1.29% Nasdaq Down 3.25%

    More On THRX

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    Ownership

    Financials

    • Income Statement
    • Balance Sheet
    • Cash Flow

    Theravance Inc. (THRX)

    -NasdaqGS
    9.81 0.00(0.00%) Jan 8, 4:00PM EST
    Prev Close:9.81
    Open:N/A
    Bid:N/A
    Ask:N/A
    1y Target Est:10.20
    Beta:2.94097
    Earnings Date:Feb 16 - Feb 22 (Est.)
    Day's Range:N/A - N/A
    52wk Range:6.36 - 21.16
    Volume:0
    Avg Vol (3m):867,484
    Market Cap:1.15B
    P/E (ttm):N/A
    EPS (ttm):-0.34
    Div & Yield:1.00 (10.19%)
    Quotes delayed, except where indicated otherwise. Currency in USD.

    Comparison

    Symbol% ChgMkt Cap
    THRX 0.00%1.15B
    PFEUp 0.10%179.22B
    AZNDown 1.44%75.92B

    Key Statistics

    Forward P/E (1 yr):N/A
    P/S (ttm):N/A
    Ex-Dividend Date:N/A

    Analysts

    Annual EPS Est () :N/A
    Quarterly EPS Est () :N/A
    Mean Recommendation*:N/A
    PEG Ratio (5 yr expected):N/A

    * (Strong Buy) 1.0 - 5.0 (Sell)

    Analyst Opinion | Estimates

    Business Summary

    Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and ... View More
    Your browser doesn't support canvas
    SETTINGS
    Scrolling
    Speed
    Display
    Price
    Submit Feedback